DrugBiological
Ibramvibart clinical trials
Also written VYD2311.
- studies test it
- 3
- open now
- 0
- in phase 3
- 2
- first study started
- 2024
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Invivyd, Inc. (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ibramvibart is read from its arms, and is right about nine times in ten.
Testing it · 3
- Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineCompletedPhase 3Invivyd, Inc.NCT07655180Written as VYD2311
- Study of VYD2311 for the Prevention of COVID-19Active, not recruitingPhase 3Invivyd, Inc.NCT07298434Written as VYD2311-SD
- A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy ParticipantsActive, not recruitingPhase 1Invivyd, Inc.NCT06523153Written as VYD2311
Codes
What other systems call ibramvibart · ClinicalTrials.gg INT017606
- UNII (FDA) PRC4J48944IBRAMVIBARTOne source FDA
- NCI Thesaurus C215285IbramvibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PRC4J48944 | IBRAMVIBART | One source FDA |
| NCI Thesaurus | C215285 | Ibramvibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.